ANN ARBOR, MI / ACCESSWIRE / May 2, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, will host a conference call and audio-only webcast on Thursday, May 11, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its first quarter ending March 31, 2023. A question-and-answer session will follow management's prepared remarks.
Event: Zomedica Q1 2023 Financial Result Conference Call
Date: Wednesday, May 11, 2023
Time: 4:30 p.m. Eastern Time
Live Call: +1-877-407-0789 (U.S. Toll-Free) or +1-201-689-8562 (International)
Webcast: https://callme.viavid.com/viavid/?callme=true&passcode=13736703&h=true&info=company&r=true&B=6
For interested individuals unable to join the conference call, a dial-in replay of the call will be available until May 25, 2023 and can be accessed by dialing +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 13738043.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica's mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Follow Zomedica
Email Alerts: http://investors.zomedica.com
LinkedIn: https://www.linkedin.com/company/zomedica
Facebook: https://m.facebook.com/zomedica
Twitter: https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Investor Relations Contact:
RedChip Companies Inc.
Barrett Boone
This email address is being protected from spambots. You need JavaScript enabled to view it.
407-571-0912
Last Trade: | US$0.04 |
Daily Change: | 0.001 2.44 |
Daily Volume: | 776,771 |
Market Cap: | US$41.160M |
August 19, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load